Browse GOSR1

Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus membrane Single-pass type IV membrane protein Note=Localizes throughout the Golgi apparatus, with lowest levels in the trans-Golgi network (By similarity). Enriched on vesicular components at the terminal rims of the Golgi. Found in Golgi microtubules at low temperature (15 degrees Celsius).
Domain -
Function

Involved in transport from the ER to the Golgi apparatus as well as in intra-Golgi transport. It belongs to a super-family of proteins called t-SNAREs or soluble NSF (N-ethylmaleimide-sensitive factor) attachment protein receptor. May play a protective role against hydrogen peroxide induced cytotoxicity under glutathione depleted conditions in neuronal cells by regulating the intracellular ROS levels via inhibition of p38 MAPK (MAPK11, MAPK12, MAPK13 and MAPK14). Participates in docking and fusion stage of ER to cis-Golgi transport. Plays an important physiological role in VLDL-transport vesicle-Golgi fusion and thus in VLDL delivery to the hepatic cis-Golgi.

> Gene Ontology
 
Biological Process GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006891 intra-Golgi vesicle-mediated transport
GO:0006903 vesicle targeting
GO:0006906 vesicle fusion
GO:0007034 vacuolar transport
GO:0016050 vesicle organization
GO:0016197 endosomal transport
GO:0016482 cytosolic transport
GO:0042147 retrograde transport, endosome to Golgi
GO:0044801 single-organism membrane fusion
GO:0048193 Golgi vesicle transport
GO:0048199 vesicle targeting, to, from or within Golgi
GO:0048209 regulation of vesicle targeting, to, from or within Golgi
GO:0048284 organelle fusion
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0060627 regulation of vesicle-mediated transport
GO:0061025 membrane fusion
GO:0090174 organelle membrane fusion
Molecular Function GO:0000149 SNARE binding
GO:0005484 SNAP receptor activity
Cellular Component GO:0005795 Golgi stack
GO:0005797 Golgi medial cisterna
GO:0005801 cis-Golgi network
GO:0030133 transport vesicle
GO:0031201 SNARE complex
GO:0031984 organelle subcompartment
GO:0031985 Golgi cisterna
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG hsa04130 SNARE interactions in vesicular transport
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-6811438: Intra-Golgi traffic
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GOSR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GOSR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.92; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GOSR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2340.251
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3510.835
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1490.904
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0410.834
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1710.917
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1230.952
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.050.88
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0060.997
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0670.97
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1690.909
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5460.796
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1390.00405
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GOSR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GOSR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GOSR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GOSR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GOSR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GOSR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GOSR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGOSR1
Namegolgi SNAP receptor complex member 1
Aliases GOS28; GS28; GOS-28; GOLIM2; golgi integral membrane protein 2; GOS28/P28; 28 kDa Golgi SNARE protein; 28 kD ......
Chromosomal Location17q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GOSR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.